Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.59 |
| ▸ | MAPT | P10636 | 5/20 | 0.56 |
| ▸ | LMNA | P02545 | 2/20 | 0.56 |
| ▸ | POLB | P06746 | 2/20 | 0.56 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.56 |
| ▸ | PTGS2 | P35354 | 2/20 | 0.55 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | RAB9A | P51151 | 1/20 | 0.53 |
| ▸ | MAOB | P27338 | 2/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.51 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Formamide SCHEMBL11664406 | 0.92 | L3MBTL1 (0.53) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL2116437 | 0.88 | PTGS2 (0.66) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL10299626 | 0.87 | PTGS2 (0.57) | L3MBTL1GAAMAPTLMNAPOLB | |
| Urethane SCHEMBL11661385 | 0.87 | POLB (0.49) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL10705419 | 0.86 | PTGS2 (0.53) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL4262664 | 0.85 | MAPT (0.70) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL3528003 | 0.85 | PLA2G4B (0.62) | MAPTPOLBPTGS2RAB9A | |
| SCHEMBL10364396 | 0.85 | PTGS2 (0.58) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL7327630 | 0.84 | L3MBTL1 (0.51) | L3MBTL1GAAMAPTLMNAPOLB | |
| SCHEMBL8770195 | 0.84 | POLB (0.70) | L3MBTL1GAAMAPTPOLBPTGS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025110772-A1 | IMIDAZOLO-PYRIDINE DERIVATIVES AND USES THEREOF | 엘젠테라퓨틱스 주식회사 | 2025-05-30 | — | — | WO | disclosed |
| US-20230200386-A1 | MONOTERPENOID/PHENYLPROPANOID-CONTAINING COMPOUNDS AND METHODS OF THEIR MAKING AND USE AS HERBICIDES | IOWA STATE UNIVERSITY RESEARCH FOUNDATION, INC. | 2023-06-29 | — | — | US | disclosed |
| US-8759355-B2 | Aryl pyrimidine derivatives, preparation methods and pharmaceutical uses thereof | INSTITUTE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. (CN) | 2014-06-24 | — | — | US | disclosed |
| US-20110009427-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | INSTITUE OF PHARMACOLOGY AND TOXICOLOGY ACADEMY OF MILITARY MEDICAL SCIENCES P.L.A. CHINA (CN) | 2011-01-13 | — | — | US | disclosed |
| EP-2184277-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | Institute Of Pharmacology And Toxicology Academy Of Military Medical Sciences P.L.A. China (CN) | 2010-05-12 | — | — | EP | disclosed |
| EP-0729465-B1 | PYRONE DERIVATIVES AS PROTEASE INHIBITORS AND ANTIVIRAL AGENTS | PARKE DAVIS & CO (US) | 2003-01-22 | — | — | EP | disclosed |
| US-6005103-A | TREATMENT OF BACTERIAL AND VIRAL INFECTIONS AND DISEASES, INCLUDING AIDS | WARNER-LAMBERT COMPANY (US) | 1999-12-21 | — | — | US | disclosed |
| US-5922717-A | ANTICOAGULANTS | DR. KARL THOMAE GMBH (DE) | 1999-07-13 | — | — | US | disclosed |
| US-5700801-A | ANTIINFLAMMATORY AGENTS, BONE DISORDERS | KARL THOMAE, GMBH (DE) | 1997-12-23 | — | — | US | disclosed |
| WO-1996020173-A1 | PIPERAZINE DERIVATIVES, MEDICAMENTS CONTAINING THE SAME, THEIR USE AND PROCESS FOR PREPARING THE SAME | DR. KARL THOMAE GMBH (DE) | 1996-07-04 | — | — | WO | disclosed |
| EP-0718287-A2 | Piperazine derivatives, medicaments containing them, their use, and processes for their preparation | Dr. Karl Thomae GmbH (DE) | 1996-06-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230200386-A1 | MONOTERPENOID/PHENYLPROPANOID-CONTAINING COMPOUNDS AND METHODS OF THEIR MAKING AND USE AS HERBICIDES | DDT, CYP4B1, GSTO1 | L3MBTL1 1489/4885GAA 1582/4885MAPT 3033/4885 |
| US-20110009427-A1 | ARYL PYRIMIDINE DERIVATIVES, PREPARATION METHODS AND PHARMACEUTICAL USES THEREOF | PPARD, PPARG, PPARA | L3MBTL1 4830/4885GAA 979/4885MAPT 4358/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.